Pages that link to "Q30439560"
Jump to navigation
Jump to search
The following pages link to Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection (Q30439560):
Displaying 31 items.
- Synergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A virus infections in mice. (Q30359363) (← links)
- Molecular determinants of influenza virus pathogenesis in mice. (Q30364868) (← links)
- The role of oseltamivir in the treatment and prevention of influenza in children. (Q30364977) (← links)
- Reduction of Neuraminidase Activity Exacerbates Disease in 2009 Pandemic Influenza Virus-Infected Mice (Q30392198) (← links)
- Characterization of Oseltamivir-Resistant 2009 H1N1 Pandemic Influenza A Viruses (Q30394067) (← links)
- Comprehensive assessment of 2009 Pandemic Influenza a (H1N1) Virus Drug Susceptibility in vitro (Q30397287) (← links)
- Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice (Q30414428) (← links)
- Newer influenza antivirals, biotherapeutics and combinations (Q30456363) (← links)
- Oseltamivir treatment prevents the increased influenza virus disease severity and lethality occurring in chronic ethanol consuming mice (Q34020714) (← links)
- Evolution of oseltamivir resistance mutations in Influenza A(H1N1) and A(H3N2) viruses during selection in experimentally infected mice. (Q34597005) (← links)
- Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus (Q35758840) (← links)
- Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates. (Q35860081) (← links)
- Loss of the N-linked glycan at residue 173 of human parainfluenza virus type 1 hemagglutinin-neuraminidase exposes a second receptor-binding site. (Q36845779) (← links)
- Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system (Q37204154) (← links)
- Animal models for the study of influenza pathogenesis and therapy (Q37379466) (← links)
- The next ten stories on antiviral drug discovery (part E): advents, advances, and adventures (Q37618653) (← links)
- The neuraminidase inhibitor oseltamivir is effective against A/Anhui/1/2013 (H7N9) influenza virus in a mouse model of acute respiratory distress syndrome (Q37696588) (← links)
- Influenza pharmacotherapy: present situation, strategies and hopes (Q37857854) (← links)
- Defective interfering influenza virus confers only short-lived protection against influenza virus disease: Evidence for a role for adaptive immunity in DI virus-mediated protection in vivo (Q38268152) (← links)
- Oseltamivir-resistant influenza A(H1N1)pdm09 virus in southern Brazil (Q39092470) (← links)
- Recent advances in the Overman rearrangement: synthesis of natural products and valuable compounds. (Q39168195) (← links)
- Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection (Q40094068) (← links)
- Emergence of Oseltamivir-Resistant H7N9 Influenza Viruses in Immunosuppressed Cynomolgus Macaques (Q41933615) (← links)
- Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice (Q42111794) (← links)
- Children with cancer and respiratory viral infection: epidemiology, diagnosis and treatment options (Q43731586) (← links)
- Viral loads and duration of viral shedding in adult patients hospitalized with influenza. (Q43873120) (← links)
- A pharmacologically immunosuppressed mouse model for assessing influenza B virus pathogenicity and oseltamivir treatment (Q45325322) (← links)
- Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system (Q47593385) (← links)
- Anti-influenza therapy: the emerging challenge of resistance (Q58066873) (← links)
- Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus (Q58614971) (← links)
- Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models. (Q64901554) (← links)